LXRX Lexicon Pharmaceuticals, Inc.
High-Growth Software
F 30.0 / 100 pillar composite

AlphaQuality composite grade, weighted for high-growth software businesses.

⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.

Grade overrides the 30.0 pillar composite — hard gates always win.

Profitability

Weight: 15%
D- 30
  • 5yr Avg ROIC -55.1%
  • Operating Margin Trend +13010.83 pp/yr

Capital Efficiency

Weight: 15%
F 0
  • 5yr Avg ROE -114.9%
  • 5yr Share-Count CAGR 25.7%

Growth Quality

Weight: 35%
B- 64
  • 5yr Revenue CAGR 259.6%
  • 5yr EPS CAGR 0.0%
  • Revenue-Growth Years (5) 3/5

Cash Generation

Weight: 20%
F 0
  • 5yr FCF Margin -21737.2%
  • 5yr FCF/NI Conversion 0.00x

Balance Sheet

Weight: 10%
F 0
  • Net Debt / EBITDA 10.00x
  • Interest Coverage (EBIT/Int) -5.87x
  • Altman Z-Score -1.00

Stability

Weight: 5%
B 73
  • EPS Volatility (σ/μ) 0.00
  • Piotroski F-Score 4
  • Negative-Revenue Years (5) 2/5

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Holding

1 of 1 gurus held; 1 added.

Holders
1
Avg Δ position
+2651.4%
New buys
0
Full exits
0
  • Wood increased +2651%
As of Q1 2026